Angiogenic Signaling Counteracts Shear Stress-driven Arterial Patterning.

This study reveals that VEGF signaling acts as a physiological brake that suppresses flow-driven arterial specification by inhibiting Sox17 activity, thereby ensuring that angiogenesis and arterial patterning occur in a spatiotemporally coordinated manner during postnatal vascular morphogenesis.

The Gist

Imagine your body's blood vessels are like a bustling city under construction. To build this city, you need two main things: new roads (to expand the network) and road upgrades (turning small dirt paths into major highways).

This paper reveals a fascinating "traffic rule" that the body uses to decide when to build new roads and when to upgrade them. The rule involves two key characters: VEGF (the Construction Manager) and Blood Flow (the Traffic).

Here is the story of how they work together, explained simply:

1. The Two Characters

• VEGF (The Construction Manager): This is a signal that tells cells, "Go! Build more roads!" It's essential for creating the initial network of tiny capillaries (the dirt paths) where there are none. It keeps the cells busy, growing, and multiplying.
• Blood Flow / Shear Stress (The Traffic): Once the roads are built and blood starts rushing through them, the physical force of that flow (like wind against a sail) sends a different signal: "Stop building! Upgrade this road into a highway!" This force tells the cells to stop multiplying and start turning into strong, specialized artery cells.

2. The Big Misunderstanding

For a long time, scientists thought VEGF was the boss of both jobs. They believed VEGF told cells to build roads and then told them to become highways.

The paper says: "Actually, no."

The researchers discovered that VEGF and Blood Flow are actually rivals when it comes to turning a capillary into an artery.

• Blood Flow wants to turn the road into a highway.
• VEGF says, "No, not yet! Keep it a small road so we can keep building more!"

3. The "Brake" Analogy

Think of the blood vessel as a car.

• Blood Flow is the gas pedal. It pushes the car forward toward becoming a strong artery.
• VEGF is the brake. As long as VEGF is pressed down, the car cannot speed up into "highway mode," even if the gas pedal (blood flow) is being pushed.

Why is this good?
In the early stages of building a city, you don't want your new dirt roads to immediately turn into highways. You want them to stay flexible so you can branch them out and build more of them. VEGF acts as a physiological brake to stop the roads from upgrading too early. It keeps the "construction zone" open so the network can expand.

4. The "Arterial Delta" (The No-Man's Land)

The researchers found a specific zone in the developing eye (the retina) called the "Arterial Delta."

• This is the area right at the edge of the construction zone.
• Here, you have high VEGF (lots of construction signals) and blood flow (traffic is starting).
• Because the VEGF "brake" is still pressed, the blood flow cannot upgrade these roads yet. They stay as capillaries.
• This creates a perfect gap: The center of the city has highways (arteries), the edge has new dirt roads (sprouting capillaries), and the middle zone is a mix that hasn't upgraded yet.

5. What Happens When the Brake Breaks?

The scientists tested this by removing the "brake" (blocking VEGF) in mice.

• Result: The construction manager (VEGF) was gone.
• The Chaos: Without the brake, the "gas pedal" (blood flow) took over immediately. The tiny capillaries at the very edge of the network, which should have been building new roads, suddenly upgraded into highways.
• The Consequence: The city lost its ability to expand. The "construction zone" turned into highways too early, leaving no room for new roads to grow. The capillary bed shrank, and the body couldn't build a proper network.

6. The Secret Mechanism: The "Foreman" (Sox17)

How does the blood flow actually upgrade the road? It uses a specific protein called Sox17. Think of Sox17 as the Foreman who directs the construction crew to lay down the heavy asphalt for highways.

• Blood Flow wakes up the Foreman (Sox17), who starts the upgrade.
• VEGF sneaks in and ties the Foreman's hands. Even if the Foreman is awake, he can't do his job because VEGF is blocking him.
• Once the construction is done and VEGF fades away, the Foreman is free to turn the dirt paths into highways.

The Takeaway

This paper changes how we understand how our bodies build blood vessels.

• Old idea: VEGF builds roads and then turns them into highways.
• New idea: VEGF builds the roads and prevents them from becoming highways. Blood flow is the only thing that turns them into highways, but it can only do so once VEGF steps aside.

It's a perfect dance: VEGF expands the network, and the removal of VEGF allows the flow to organize it. If you mess up this timing, you get a broken network where the roads upgrade before they are fully built.

Technical Summary

1. Problem Statement

Postnatal vascular morphogenesis involves two distinct but overlapping processes: angiogenesis (expansion of the capillary bed via sprouting) and arterial patterning (remodeling of capillaries into arteries).

• The Paradox: While Vascular Endothelial Growth Factor A (VEGF-A) is the primary driver of angiogenesis, previous studies suggested it also promotes arterial specification via Notch signaling. However, in the developing mouse retina, arterialization occurs in regions where VEGF levels have declined, while the angiogenic front (highest VEGF) remains non-arterial.
• The Knowledge Gap: It was unclear why angiogenesis and arterial patterning are spatiotemporally segregated. Specifically, it was unknown whether VEGF signaling is required for arterial fate specification or if it plays a different role, and how VEGF interacts with Fluid Shear Stress (FSS), a known driver of arterial specification.

2. Methodology

The authors employed a multi-faceted approach combining in vitro cell biology, in vivo mouse models, and computational systems biology:

• In Vitro Models:

  • Used Human Microvascular Blood Endothelial Cells (HMVBECs) and Human Umbilical Vein Endothelial Cells (HUVECs).
  • Applied four conditions: Static (ST), VEGF alone, Laminar Flow (FSS), and FSS + VEGF.
  • Utilized siRNA knockdown (PLCγ1), CRISPR-Cas9 (Sox17/Sox18 knockout), and inducible Sox17 overexpression.
  • Assessed gene expression via RNA-seq, RT-qPCR, and Western blotting.
  • Performed Chromatin Immunoprecipitation (ChIP) to assess Sox17 binding to promoters/enhancers.

• In Vivo Models (Mouse Retina):

  • Genetic Models: Used inducible knockout mice:
    • Vegfa^iKO (global VEGF deletion).
    • Vegfr2^iECKO (endothelial-specific VEGFR2 deletion).
    • Plcg1^iECKO (endothelial-specific PLCγ1 deletion, a primary VEGFR2 effector).
  • Pharmacological Blockade: Treated neonatal mice with DC101 (anti-VEGFR2 neutralizing antibody).
  • Imaging & Quantification: Immunostaining for arterial markers (Sox17, SMA), capillary markers (IB4), and proliferation markers (EdU, pERK). Measured "Arterial Extension" (ratio of artery length to total radial outgrowth) and the "Un-arterialized Gap."
  • Perfusion Assays: Retro-orbital injection of IB4-Alexa488 to distinguish perfused (flow-exposed) vs. non-perfused vessels.
  • Single-Cell RNA Sequencing (scRNA-seq): Analyzed endothelial cells from control and Plcg1^iECKO retinas to map cell state transitions.

• Computational Analysis:

  • cSTAR (Cell State Transition Assessment and Regulation): A systems biology approach using Support Vector Machines (SVM) to define metastable cell states and calculate State Transition Vectors (STVs) and Dynamic Phenotype Descriptors (DPDs).
  • Trajectory Analysis: Used TSCAN and RNA Velocity to map differentiation trajectories from capillary to arterial states.

3. Key Contributions & Findings

A. VEGF Acts as a Physiological Brake on Arterialization

• In Vitro: FSS robustly induces arterial genes (e.g., Gja4, Gja5, Sox17, Efnb2). However, the addition of VEGF dose-dependently inhibits this FSS-induced arterial program, maintaining the capillary fate.
• In Vivo: In the developing retina, arterialization occurs only in regions where VEGF activity has declined (central retina), despite the presence of FSS. The "Angiogenic Front" (high VEGF) remains a capillary bed.
• The "Arterial Delta" (AΔ): The authors identified a specific region between the arterial tip and the angiogenic front. This region is exposed to FSS but remains non-arterial due to high VEGF levels.

B. Arterial Specification is Independent of VEGF Signaling

• Contrary to the hypothesis that VEGF is required for arterial fate, loss-of-function models (Vegfa^iKO, Vegfr2^iECKO, Plcg1^iECKO, and DC101 treatment) resulted in intact but ectopic arterialization.
• In these models, arteries extended fully to the vascular front, eliminating the "un-arterialized gap." This indicates that FSS can drive arterial specification even in the absence of VEGF signaling, and that VEGF normally prevents this from happening in the capillary bed.

C. Mechanism: VEGF Antagonizes Sox17 Transcriptional Activity

• Sox17 is the Key Driver: Sox17 is identified as the essential mechanosensitive transcription factor for the FSS-induced arterial program. Loss of Sox17 blocks arterial gene induction, while overexpression induces arterial genes even without flow.
• The Antagonism: VEGF does not reduce Sox17 protein levels. Instead, it compromises the transcriptional activity of Sox17.
• ChIP Evidence: In the presence of VEGF, the enrichment of Sox17 on arterial promoters (e.g., Gja5, Gja4) and enhancers is significantly reduced. VEGF signaling effectively "turns off" the Sox17-mediated transcriptional program required for arterial fate, even when FSS is present.

D. Notch Signaling is Not the Primary Mediator

• While Notch signaling is involved in some arterial genes, inhibiting Notch (via DAPT) did not prevent VEGF from suppressing FSS-induced arterialization. This suggests the VEGF-Sox17 axis operates independently of the canonical VEGF-Notch feedback loop in this context.

4. Significance

• New Paradigm in Vascular Biology: The study overturns the view that VEGF promotes arterial specification. Instead, it establishes VEGF as a physiological brake that prevents premature arterialization of the capillary bed.
• Spatiotemporal Coordination: It explains how the vascular system coordinates growth and patterning:
  1. High VEGF / Low FSS: Promotes angiogenesis (sprouting) and maintains capillary identity.
  2. Low VEGF / High FSS: Permits FSS to drive the capillary-to-artery transition.
• Therapeutic Implications: Understanding this "brake" mechanism is crucial for regenerative medicine and tissue engineering. To successfully engineer arterial networks, one must ensure the cessation of VEGF signaling to allow flow-driven arterial specification. Conversely, preventing ectopic arterialization in pathological angiogenesis (e.g., tumors) might involve modulating this VEGF-FSS balance.
• Systems Biology Insight: The application of cSTAR analysis provided a quantitative framework to demonstrate that VEGF and FSS drive endothelial cells into distinct, mutually exclusive metastable states, rather than additive ones.

Conclusion

The paper demonstrates that angiogenic signaling (VEGF) counteracts fluid shear stress-driven arterial patterning by inhibiting the transcriptional activity of the mechanosensitive factor Sox17. This mechanism ensures that the capillary bed expands first (angiogenesis) and only remodels into arteries (arterial patterning) once VEGF levels subside, preventing the loss of the essential capillary network.